罗氟司特2022价格,多少钱一盒？

How much does a box of Roflumilast cost in 2022?

Roflumilast is a PDE-4 inhibitor approved by the U.S. Food and Drug Administration. It was successfully developed for the first time by the German company Altana and launched in the United States in 2011. In May 2016, AstraZeneca acquired the rights to roflumilast in other countries or regions by acquiring Takeda Pharmaceutical's respiratory drug business. However, it is not currently on the market in China. Patients cannot buy roflumilast in domestic hospital pharmacies, and there is no price information released.

It is understood that the current price of roflumilast in overseas markets is not fixed due to exchange rate fluctuations. The current reference price is probably the British AstraZeneca version of roflumilast (roflumilast, direct mail from Germany):

A box of 500μg*30 tablets costs $1,700;

A box of 500μg*90 tablets costs $2850.

How much does it cost to take Roflumilast for one month?

The recommended dosage of roflumilast for patients with severe chronic obstructive pulmonary disease (COPD) is 500 mcg once daily, with or without food. That is to say, you need one piece of roflumilast every day, and one box of 500 μg*30 tablets is needed for a month; one box of 500 μg*90 tablets can last about three months. Relatively speaking, the 2850$ box of 500 μg*90 tablets is more cost-effective. Patients can also choose according to their own circumstances. They can go abroad to purchase medicines, or obtain them through domestic professional overseas medical service institutions. They are guaranteed to be genuine and at affordable prices. For more details, you can consult customer service personnel. Signing a contract for overseas medicines will provide greater protection.

Roflumilast is used to treat severe chronic obstructive pulmonary disease (COPD) and hypermucus bronchitis cough, bronchial asthma, wheezing bronchitis, acute and chronic bronchitis with abnormal respiratory secretion, air sacculitis, etc. Roflumilast selectively inhibits PDE4 and blocks inflammatory response signaling, thereby inhibiting the damage to lung tissue caused by respiratory diseases such as COPD and asthma.

Recommended related articles: